T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

Catakovic, K; Klieser, E; Neureiter, D; Geisberger, R; Cell Commun Signal. 2017; 15(1):

Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation.

Greil, R; Hutterer, E; Hartmann, TN; Pleyer, L; Cell Commun Signal. 2017; 15(1):5

Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.

Taylor, N; Kremser, I; Auer, S; Hoermann, G; Greil, R; Haschke-Becher, E; Esterbauer, H; Kenner, L; Oberkofler, H; J Acquir Immune Defic Syndr. 2017; 75(1):e13-e20

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkins lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann, P; Haverkamp, H; Lohri, A; Mey, U; Kreissl, S; Greil, R; Markova, J; Feuring-Buske, M; Meissner, J; Dührsen, U; Ostermann, H; Keller, U; Maschmeyer, G; Kuhnert, G; Dietlein, M; Kobe, C; Eich, H; Baues, C; Stein, H; Fuchs, M; Diehl, V; Engert, A; Lancet Oncol. 2017; 18(4): 454-463.

Multiple myeloma of the mandibular condyle: a rare presentation.

Bottini, GB; Steiner, C; Melchardt, T; Gaggl, A; Br J Oral Maxillofac Surg. 2017; 55(10):1046-1047

Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion-Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction.

Wernly, B; Gonçalves, I; Kiss, A; Paar, V; Mösenlechner, T; Leisch, M; Santer, D; Motloch, L; Klein, KU; Tretter, EV; Kretzschmar, D; Podesser, B; Jung, C; Hoppe, UC; Lichtenauer, M; Biotechnol J. 2017; 12(9):

Antiangiogenic therapy in breast cancer.

Gampenrieder, SP; Westphal, T; Greil, R; Memo. 2017; 10(4):194-201

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group.

Engert, A; Goergen, H; Markova, J; Pabst, T; Meissner, J; Zijlstra, JM; Král, Z; Eichenauer, DA; Soekler, M; Greil, R; Kreissl, S; Scheuvens, R; Eich, H; Kobe, C; Dietlein, M; Stein, H; Fuchs, M; Diehl, V; Borchmann, P; Hemasphere. 2017; 1(1): e5

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Kazianka, L; Drucker, C; Skrabs, C; Thomas, W; Melchardt, T; Struve, S; Bergmann, M; Staber, PB; Porpaczy, E; Einberger, C; Heinz, M; Hauswirth, A; Raderer, M; Pabinger, I; Thalhammer, R; Egle, A; Wendtner, CM; Follows, G; Hoermann, G; Quehenberger, P; Jilma, B; Jaeger, U; Leukemia. 2017; 31(5): 1117-1122.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter, B; Willenbacher, E; Willenbacher, W; Egle, A; Neumeister, P; Voskova, D; Mayerhoefer, ME; Simonitsch-Klupp, I; Melchardt, T; Greil, R; Raderer, M; Blood. 2017; 129(3):-385